A computer rendering of packaging for Beyfortus, a new shot for babies that protects them from being hospitalized with respiratory syncytial virus, or RSV. Courtesy Astra Zeneca

(CNN) — A highly anticipated new shot that can protect newborns from the ravages of respiratory syncytial virus may not be available to some families this season because of uncertainties about insurance coverage.

When the US Food and Drug Administration approved the antibody, nirsevimab, in July, pediatricians and parents were jubilant. RSV fills hospitals every winter with babies who are struggling to breathe. As many as 80,000 kids under the age of 5 are hospitalized annually in the United States with this infection, and up to 300 die, according to the US Centers for Disease Control and Prevention.

Please click here for the rest of the article.